Ahmed Obeidat
Neurology · Milwaukee, WINPI 1184069627
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,290,712 of the $1,884,283 with a category attached, or 68.5%. It is spread thinly across 21 manufacturers, the largest accounting for just 23.4%. Among neurology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,506 payments — averaging $1251.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$441K
- AstraZeneca$377K
- Amgen$294K
- Biogen$253K
- E.r. Squibb & Sons, L.L.C.$124K
- TG Therapeutics, Inc.$85K
- plus $310K from 15 others
Across 367 payments — averaging $11,156 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.7M
- Novartis$1.4M
- Sanofi$242K
- Bristol Myers Squibb$210K
- TG Therapeutics, Inc.$154K
- E.r. Squibb & Sons, L.L.C.$80K
- plus $311K from 8 others
What the payments were for
- Consulting fees$399,37121%
- Speaking & faculty fees$1,290,71268%
- Travel & lodging$154,2888%
- Food & beverage$39,7982%
- Education$1140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 329 | $440,504 |
| AstraZeneca | 306 | $376,871 |
| Amgen(2 entities) | 255 | $294,295 |
| Biogen | 174 | $253,365 |
| E.r. Squibb & Sons, L.L.C. | 64 | $124,142 |
| TG Therapeutics, Inc. | 73 | $84,857 |
| Sanofi | 40 | $79,231 |
| Genentech USA, Inc. | 52 | $67,997 |
| Novartis | 90 | $56,300 |
| Bristol Myers Squibb | 84 | $38,419 |
| F. Hoffmann-la Roche AG | 12 | $21,170 |
| Ares Trading SA | 7 | $18,775 |
| Merck Healthcare Kgaa | 1 | $6,950 |
| Greenwich Biosciences, Inc. | 3 | $6,688 |
| Banner Life Sciences, LLC | 7 | $6,448 |
| Merck Kgaa | 1 | $3,128 |
| Genentech, Inc. | 4 | $2,285 |
| BD | 1 | $1,425 |
| Novartis Pharma AG | 1 | $1,175 |
| AbbVie | 1 | $145 |
| Medtronic | 1 | $115 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,884,283 in reported general payments places this provider in the 95th percentile of 308 neurology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MavencladCladribine | 16 | $1,312,646 |
| Kesimpta PenOfatumumab | 54 | $494,290 |
| VumerityDiroximel Fumarate | 21 | $209,205 |
| EnspryngSatralizumab-Mwge | 12 | $193,748 |
| CopaxoneGlatiramer Acetate | 19 | $109,029 |
| MyrbetriqMirabegron | 24 | $18,231 |
| Dalfampridine ErDalfampridine | 55 | $16,407 |
| Teriflunomide | 51 | $7,407 |
| Tizanidine Hcl | 84 | $5,346 |
| Baclofen | 113 | $4,830 |
| Modafinil | 50 | $2,349 |
| Gabapentin | 70 | $2,001 |
| Duloxetine Hcl | 19 | $1,868 |
| Armodafinil | 12 | $1,201 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 15 | $1,033 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Mavenclad | $440,504 | $1,312,64616 claims |
| BiogenVumerity | $253,365 | $209,20521 claims |
| Genentech USA, Inc.Enspryng | $67,997 | $193,74812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 neurology providers in Wisconsin.
Other neurology in Milwaukee
- Bhupendra KhatriMilwaukee$2.5M
- Staley BrodMilwaukee$1M
- Sam HooshmandMilwaukee$229K
- Fallon SchloemerMilwaukee$48K
- Thulasirman RavichandranMilwaukee$47K
- Julia CollinsMilwaukee$21K
- Ryan BrennanMilwaukee$20K
- Elise JohnsonMilwaukee$11K
- Janel SchneiderMilwaukee$9K
- Teresa LeeMilwaukee$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.